CDK Inhibitors in Normal and Malignant Cells

A. Besser, J. Slingerland

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The present article provides a general review of the function and regulation of the best understood CDK inhibitors, p15INK4b, p16INK4a, p21Cip1, and p27Kip1 in normal cells. Mechanisms of CDK inhibitor regulation in normal cells are briefly reviewed, as is their deregulation and potential prognostic significance in human cancers. The article addresses how CDK inhibitors govern not only cell cycle progression but how they are implicated in regulation of diverse processes, including senescence, programmed cell death, transcription factor corepression and cell motility and invasion. Several of these functions have been shown to be misregulated in cancers and the potential for CDK inhibitor levels or localization to serve as markers/predictors of oncogenic pathway activation and responsiveness to targeted therapies is discussed.

Original languageEnglish (US)
Title of host publicationFunctional Cell Biology
PublisherElsevier Inc.
Pages437-446
Number of pages10
Volume3
ISBN (Electronic)9780123944474
ISBN (Print)9780123947963
DOIs
StatePublished - Jan 1 2016

Keywords

  • CDK
  • CDK inhibitor
  • Cancer
  • Cell cycle
  • Cyclin
  • INK4a
  • INK4b
  • MEK/MAPK
  • P21
  • P27
  • PI3K/mTOR
  • Src

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'CDK Inhibitors in Normal and Malignant Cells'. Together they form a unique fingerprint.

  • Cite this

    Besser, A., & Slingerland, J. (2016). CDK Inhibitors in Normal and Malignant Cells. In Functional Cell Biology (Vol. 3, pp. 437-446). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394447-4.30059-1